Histone Deacetylase 6 (HDAC6) As A Therapeutic Target in Chronic Lymphocytic Leukemia
Poster Dec 13, 2017
Kamira K. Maharaj, John Powers, Susan L. Deng, Alex Achille, Mibel Pabon-Saldana, Renee Fonseca, Steven N. Quayle, Simon S. Jones, Eva Sahakian and Javier Pinilla-Ibarz
Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in the western world and is characterized by an accumulation of CD5+ B cells in circulation and lymphoid tissue. There is a need to identify novel therapies for CLL patients due to prevalence of partial responses and relapsed/refractory disease. In CLL, an immunosuppressive phenotype enables the malignant B cell to evade immune detection, leading to immune suppression. In recent years, epigenetic changes prompted by proteins known as histone deacetylases (HDACs) have gained special attention predominantly because of their active role in the regulation of pathogenesis and immune-related pathways in CLL; though the precise mechanism by which these regulatory events take place has yet to be elucidated. In addition to the well-recognized role of histone deacetylase inhibitors (HDACi) in the control of cell cycle and apoptosis, HDACi have a potential role in modulating the immunobiology of CLL. HDACs may therefore represent viable targets to develop new immunomodulating therapies for CLL.
In this study, we aimed to investigate the role of histone deacetylase 6 (HDAC6) in immunobiology of CLL and determine how HDAC6 may regulate malignant B cell survival pathways. Further, we aimed to determine efficacy of HDAC6 inhibition in a CLL murine model.
Collectively our data confirms the importance of HDAC6 to CLL progression. We have found that HDAC6 inhibition regulates CLL immunobiology to deter tumor cell immune evasion mechanisms and reinvigorate a beneficial immune response against CLL disease. Results from our preclinical CLL models suggest that HDAC6 represents a viable therapeutic target in CLL. This target may be developed with the intention to treat relapsed/refractory CLL patients or weaker, aged patients.
Psychiatric Risk Gene Cacna1c and Early Life Stress: Potential Gene-Environment interactions?Poster
Early life stress (ELS) is highly associated with development of psychopathology
and mood disorders in adulthood. Genetic studies have identified variation in the gene calcium voltage-gated channel subunit alpha1C (CACNA1C) to increase risk for several psychiatric disorders. This poster assessed the expression of Cacna1c following prepubertal stress.
Treatment Options for Chronic Parvovirus Viremia in Pediatric Heart Transplant Patients in a Tertiary Care CenterPoster
This abstract discusses three cases of pediatric heart transplant patients who suffered from parvovirus (B19) infection. Of these patients, two ( B & C) responded well to standard intravenous Ig therapy. Patient A however, did not respond to standard treatment and was begun on subcutaneous Ig, which effectively diminished his viral load. Thus, subcutaneous Ig infusions might serve as a second line treatment for transplant patients with parvovirus who do not respond well to the standard approach.READ MORE
T-helper cell phenotype expression in cutaneous lesions of angioimmunoblastic T-cell lymphomaPoster
Angioimmunoblastic T-cell lymphoma (AITL) is a common type of peripheral T-cell lymphoma. AITL can be missed until lymphadenopathy develops in patients initially presenting with skin lesions, as skin biopsy may lack conclusive findings. Our case highlights the extranodal presentation of AITL with cutaneous lesions displaying the TFH phenotype.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018